{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:08:54Z","timestamp":1780337334485,"version":"3.54.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gaucher disease (GD) is a lysosomal disease caused by mutations in the\u00a0\n                      <jats:italic>GBA1<\/jats:italic>\n                      \u00a0gene, leading to glucosylceramide and glucosylsphingosine accumulation.\u00a0\n                      <jats:italic>GBA1<\/jats:italic>\n                      \u00a0mutations are also the most common genetic risk factor for Parkinson\u2019s disease (PD). Increased expression of glycoprotein non-metastatic melanoma protein B (gpNMB), a potential biomarker of inflammation and neurodegeneration, has been reported in PD, GD and other LSDs. Plasma concentrations of gpNMB are correlated with the accumulation of bioactive lipid substrates in several chronic inflammatory diseases and gpNMB stimulates lipogenesis in white adipocytes. To explore its potential significance in GD we measured plasma gpNMB in patients with Gaucher Disease type 1 (GD1), Gaucher Disease Type 3 (GD3), GD1-PD, PD and\u00a0\n                      <jats:italic>GBA<\/jats:italic>\n                      \u00a0heterozygous PD and in different clinicopathological subtypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study enrolled participants the GAUCHERITE Cohort in the UK (172 GD1 and 20 GD3 patients) and the Biopark Cohort (72 IPD patients) in Sweden. Plasma concentrations of gpNMB were significantly higher in patients with Gaucher disease (mean: 200.9; range: 9.8-1643 ng\/ml) compared with healthy controls (mean: 35.1; range.: 10.1- 125 ng\/ml), including those receiving enzyme replacement therapy (ERT). Notably, gpNMB concentrations remained elevated in GD1 patients who had received ERT for more than 5 years. The biomarker was particularly elevated in patients who had been splenectomized, those with known pulmonary or liver disease, and those with monoclonal gammopathy, despite enzyme therapy. No statistical difference was found in plasma gpNMB concentrations between treated patients with GD1 and GD3. On average, there was no difference in plasma gpNMB concentrations between Gaucher patients with or without Pakinsonism. As expected however plasma gpNMB concentrations among patients with Parkinsonism were higher in those with type 1 Gaucher disease than either\n                      <jats:italic>GBA1<\/jats:italic>\n                      heterozygotes or those with idiopathic PD (p=0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that the association of plasma gpNMB with liver cirrhosis, gammopathy and pulmonary disease in Gaucher disease warrants further investigation. Additionally, plasma gpNMB may serve as a supportive biomarker in the evaluation and clinical monitoring of residual disease activity. However, plasma gpNMB neither differentiated between the neuronopathic subtypes of Gaucher disease nor idiopathic Parkinson\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04054-y","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:50:15Z","timestamp":1761655815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypes"],"prefix":"10.1186","volume":"20","author":[{"given":"Sebile","family":"Kilavuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri-Lee","family":"Wallom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Catarina Gomes Almeida Augusto","family":"Ca\u00e7ote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e","family":"Donald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Yew","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"te Vruchte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sturchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Tsitsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Andr\u00e9asson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Markaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7614-0403","authenticated-orcid":false,"given":"Frances M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the MRC GAUCHERITE Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"4","key":"4054_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","volume":"10","author":"TM Cox","year":"1997","unstructured":"Cox TM, Schofield JP. Gaucher\u2019s disease: Clinical features and natural history. Baillieres Clinhaematol. 1997;10(4):657\u201389.","journal-title":"Baillieres clinhaematol"},{"issue":"3","key":"4054_CR2","doi-asserted-by":"publisher","first-page":"e0120194","DOI":"10.1371\/journal.pone.0120194","volume":"10","author":"H Zigdon","year":"2015","unstructured":"Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH. Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of gaucher disease. PLoS One. 2015;10(3):e0120194.","journal-title":"PLoS One"},{"issue":"4","key":"4054_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J","volume":"12","author":"M Horowitz","year":"1998","unstructured":"Horowitz M, Pasmanik-Chor M, Borochowitz Z, Falik-Zaccai T, Heldmann K, Carmi R, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat. 1998;12(4):240\u201344.","journal-title":"Hum.Mutat"},{"issue":"3","key":"4054_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"2","key":"4054_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","volume":"22","author":"L Nalysnyk","year":"2017","unstructured":"Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: A comprehensive review of the literature. Hematology. 2017;22(2):65\u201373.","journal-title":"Hematology"},{"issue":"1","key":"4054_CR6","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1542\/peds.105.1.e10","volume":"105","author":"DA Applegarth","year":"2000","unstructured":"Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000;105(1):e10.","journal-title":"Pediatrics"},{"issue":"6","key":"4054_CR7","first-page":"363","volume":"26","author":"HA Ozkara","year":"2004","unstructured":"Ozkara HA, Topcu M. Sphingolipidoses in Turkey. Brain Dev. 2004;26(6):363\u201366.","journal-title":"BrainDev"},{"key":"4054_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, et al. The French Gaucher\u2019s disease registry: Clinical characteristics, complications and treatment of 562 patients. Orphanet J Raredis. 2012;7:77.","journal-title":"Orphanet J raredis"},{"issue":"3","key":"4054_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1067\/mpd.2002.122394","volume":"140","author":"C Dionisi-Vici","year":"2002","unstructured":"Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, Abeni D. Inborn errors of metabolism in the Italian pediatric population: A national retrospective survey. J Pediatr. 2002;140(3):321\u201327.","journal-title":"JPediatr"},{"issue":"1","key":"4054_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: Findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166(1):172\u201377.","journal-title":"JPediatr"},{"issue":"12","key":"4054_CR11","first-page":"1258","volume":"103","author":"M Hult","year":"2014","unstructured":"Hult M, Darin N, von Dobeln U, Mansson JE. Epidemiology of lysosomal storage diseases in Sweden. Acta Paediatr. 2014;103(12):1258\u201363.","journal-title":"ActaPaediatr"},{"issue":"9813","key":"4054_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379(9813):335\u201341.","journal-title":"Lancet"},{"issue":"2","key":"4054_CR13","first-page":"106","volume":"24","author":"TM Cox","year":"2001","unstructured":"Cox TM. Gaucher disease: Understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metabdis. 2001;24(2):106\u201321; discussion 87-8.","journal-title":"J Inherit metabdis"},{"issue":"3","key":"4054_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0005-2760(82)90272-7","volume":"712","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Mansson JE, Hakansson G, Svennerholm L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher\u2019s disease. Biochim Biophys Acta. 1982;712(3):453\u201363.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4054_CR15","first-page":"233","volume":"48","author":"E Orvisky","year":"2000","unstructured":"Orvisky E, Sidransky E, McKinney CE, Lamarca ME, Samimi R, Krasnewich D, et al. Glucosylsphingosine accumulation in mice and patients with type 2 gaucher disease begins early in gestation. Pediatr Res. 2000;48(2):233\u201337.","journal-title":"PediatrRes"},{"issue":"2","key":"4054_CR16","first-page":"59","volume":"132","author":"GA Grabowski","year":"2021","unstructured":"Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: Basic and translational science needs for more complete therapy and management. Mol Genet Metab. 2021;132(2):59\u201375.","journal-title":"Mol GenetMetab"},{"issue":"1","key":"4054_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s13023-021-02034-6","volume":"16","author":"S D\u2019Amore","year":"2021","unstructured":"D\u2019Amore S, Page K, Donald A, Taiyari K, Tom B, Deegan P, et al. In-depth phenotyping for clinical stratification of gaucher disease. Orphanet J Raredis. 2021;16(1):431.","journal-title":"Orphanet J raredis"},{"issue":"1","key":"4054_CR18","first-page":"S25","volume":"90","author":"TM Cox","year":"2015","unstructured":"Cox TM, Rosenbloom BE, Barker RA. Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. Am JHematol. 2015;90(1):S25\u20138.","journal-title":"Am JHematol"},{"issue":"6","key":"4054_CR19","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bjh.12335","volume":"161","author":"M Arends","year":"2013","unstructured":"Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013;161(6):832\u201342.","journal-title":"Br JHaematol"},{"issue":"2","key":"4054_CR20","first-page":"109124","volume":"145","author":"A Donald","year":"2025","unstructured":"Donald A, Brothwell S, Cabello BM, Ehrstedt C, Fernandez-Fructuoso JR, Fernandez-Marin E, et al. 250 cases of \u201ctype 2 gaucher disease\u201d: A novel system of clinical categorisation and evidence of genotype: Phenotype correlation. Mol Genet Metab. 2025;145(2):109124.","journal-title":"Mol GenetMetab"},{"issue":"5","key":"4054_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jimd.12235","volume":"43","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic gaucher disease. J Inherit Metabdis. 2020;43(5):1056\u201359.","journal-title":"J Inherit metabdis"},{"key":"4054_CR22","doi-asserted-by":"crossref","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int J Molsci. 2017;18(2).","DOI":"10.3390\/ijms18020441"},{"issue":"9645","key":"4054_CR23","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372(9645):1263\u201371.","journal-title":"Lancet"},{"key":"4054_CR24","doi-asserted-by":"crossref","unstructured":"Donald A, Jones SA, Hughes DA, Church HJ, Consortium G, Cox TM. Gaucher disease type, 3: Classification of the chronic neuronopathic variant informed by genotype in a phenotypically diverse cohort. Genet Med. 2025;101502.","DOI":"10.1016\/j.gim.2025.101502"},{"issue":"2","key":"4054_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00690463","volume":"65","author":"NG Conradi","year":"1984","unstructured":"Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of gaucher disease. Morphological Biochemical Stud Acta Neuropathol. 1984;65(2):99\u2013109.","journal-title":"Morphological Biochemical Stud Acta Neuropathol"},{"issue":"5","key":"4054_CR26","first-page":"443","volume":"27","author":"O Nilsson","year":"1985","unstructured":"Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 gaucher disease variants. Clin Genet. 1985;27(5):443\u201350.","journal-title":"ClinGenet"},{"issue":"2","key":"4054_CR27","first-page":"138","volume":"127","author":"A Kurolap","year":"2019","unstructured":"Kurolap A, Del Toro M, Spiegel R, Gutstein A, Shafir G, Cohen IJ, et al. Gaucher disease type 3c: New patients with unique presentations and review of the literature. Mol Genet Metab. 2019;127(2):138\u201346.","journal-title":"Mol GenetMetab"},{"issue":"6","key":"4054_CR28","first-page":"104764","volume":"66","author":"FD Bulut","year":"2023","unstructured":"Bulut FD, Kor D, Kilavuz S, Seker Yilmaz B, Kaplan I, Ekinci F, et al. Expanding the phenotypic landscape of gaucher disease type 3c with a novel entity - transient neonatal cholestasis. Eur J Medgenet. 2023;66(6):104764.","journal-title":"Eur J medgenet"},{"issue":"10","key":"4054_CR29","first-page":"1353","volume":"65","author":"O Goker-Alpan","year":"2008","unstructured":"Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65(10):1353\u201357.","journal-title":"ArchNeurol"},{"issue":"12","key":"4054_CR30","first-page":"937","volume":"41","author":"O Goker-Alpan","year":"2004","unstructured":"Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among gaucher disease carriers. J Medgenet. 2004;41(12):937\u201340.","journal-title":"J medgenet"},{"issue":"6","key":"4054_CR31","first-page":"727","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70(6):727\u201335.","journal-title":"JAMANeurol"},{"issue":"3","key":"4054_CR32","first-page":"455","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, Schapira AH. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol. 2012;72(3):455\u201363.","journal-title":"AnnNeurol"},{"issue":"1","key":"4054_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"issue":"4","key":"4054_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Westbroek W, Sidransky E. The complicated relationship between gaucher disease and parkinsonism: Insights from a rare disease. Neuron. 2017;93(4):737\u201346.","journal-title":"Neuron"},{"key":"4054_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neuint.2015.12.004","volume":"93","author":"M Barkhuizen","year":"2016","unstructured":"Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson\u2019s disease-pathology, presentation and therapies. Neurochem Int. 2016;93:6\u201325.","journal-title":"NeurochemInt"},{"issue":"21","key":"4054_CR36","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324(21):1464\u201370.","journal-title":"N Engl JMed"},{"key":"4054_CR37","unstructured":"Pastores GM, Hughes DA. in: Adam, MP, Ardinger, HH, Pagon, RA, Wallace, SE, Bean, LJH, Mirzaa, G, Amemiya, A, editors. GeneReviews((R)). Gaucher disease. Seattle (WA)1993."},{"key":"4054_CR38","first-page":"81","volume":"6","author":"PB Deegan","year":"2012","unstructured":"Deegan PB, Cox TM. Imiglucerase in the treatment of gaucher disease: A history and perspective. Drug Des Devel Ther. 2012;6:81\u2013106.","journal-title":"Drug Des Devel Ther"},{"key":"4054_CR39","first-page":"299","volume":"4","author":"TM Cox","year":"2010","unstructured":"Cox TM. Gaucher disease: Clinical profile and therapeutic developments. Biologics. 2010;4:299\u2013313.","journal-title":"Biologics"},{"issue":"2","key":"4054_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1010335505357","volume":"24","author":"FM Platt","year":"2001","unstructured":"Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metabdis. 2001;24(2):275\u201390.","journal-title":"J Inherit metabdis"},{"issue":"11","key":"4054_CR41","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.24877","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, et al. Outcomes after 18 months of eliglustat therapy in treatment-naive adults with gaucher disease type 1: The phase 3 ENGAGE trial. Am J Hematol. 2017;92(11):1170\u201376.","journal-title":"Am JHematol"},{"issue":"17","key":"4054_CR42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","volume":"129","author":"TM Cox","year":"2017","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat maintains long-term clinical stability in patients with gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129(17):2375\u201383.","journal-title":"Blood"},{"issue":"2","key":"4054_CR43","first-page":"95","volume":"117","author":"M Balwani","year":"2016","unstructured":"Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, et al. Recommendations for the use of eliglustat in the treatment of adults with gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95\u2013103.","journal-title":"Mol GenetMetab"},{"key":"4054_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","volume":"37","author":"N Belmatoug","year":"2017","unstructured":"Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 gaucher disease in europe. Eur J Internmed. 2017;37:25\u201332.","journal-title":"Eur J internmed"},{"issue":"7\u20138","key":"4054_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00431-001-0859-7","volume":"162","author":"M Migita","year":"2003","unstructured":"Migita M, Hamada H, Fujimura J, Watanabe A, Shimada T, Fukunaga Y. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy-unsuccessful treatment of the neurological abnormality in type 2 gaucher disease. Eur J Pediatr. 2003;162(7\u20138):524\u201325.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"4054_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1023\/A:1010514614570","volume":"24","author":"A Vellodi","year":"2001","unstructured":"Vellodi A, Bembi B, de Villemeur TB, Collin-Histed T, Erikson A, Mengel E, et al. Management of neuronopathic gaucher disease: A European consensus. J Inherit Metabdis. 2001;24(3):319\u201327.","journal-title":"J Inherit metabdis"},{"key":"4054_CR47","doi-asserted-by":"crossref","unstructured":"van Eijk M, Aerts J. The unique phenotype of Lipid-Laden Macrophages. Int J Molsci. 2021;22(8).","DOI":"10.3390\/ijms22084039"},{"issue":"3","key":"4054_CR48","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of gaucher disease. J Clin Invest. 1994;93(3):1288\u201392.","journal-title":"J. clin.Invest"},{"issue":"5","key":"4054_CR49","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood.V96.5.1969","volume":"96","author":"MT Moran","year":"2000","unstructured":"Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM. Pathologic gene expression in gaucher disease: Up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 2000;96(5):1969\u201378.","journal-title":"Blood"},{"issue":"447","key":"4054_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1651-2227.2005.tb02110.x","volume":"94","author":"JM Aerts","year":"2005","unstructured":"Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG. Identification and use of biomarkers in gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl. 2005;94(447):43\u201346; discussion 37-8.","journal-title":"Acta paediatrsuppl"},{"issue":"1","key":"4054_CR51","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","volume":"17","author":"A Dardis","year":"2022","unstructured":"Dardis A, Michelakakis H, Rozenfeld P, Fumic K, Wagner J, Pavan E, et al. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet J Raredis. 2022;17(1):442.","journal-title":"Orphanet J raredis"},{"issue":"16","key":"4054_CR52","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118(16):e118\u201327.","journal-title":"Blood"},{"issue":"19","key":"4054_CR53","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1111\/j.1742-4658.2009.07259.x","volume":"276","author":"AP Bussink","year":"2009","unstructured":"Bussink AP, Verhoek M, Vreede J, Ghauharali-van der Vlugt K, Donker-Koopman WE, Sprenger RR, et al. Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. The FEBSJ. 2009;276(19):5678\u201388.","journal-title":"The FEBSJ"},{"key":"4054_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2016.12.002","volume":"68","author":"V Murugesan","year":"2018","unstructured":"Murugesan V, Liu J, Yang R, Lin H, Lischuk A, Pastores G, et al. Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of gaucher disease. Blood Cells Moldis. 2018;68:47\u201353.","journal-title":"Blood Cells moldis"},{"key":"4054_CR55","doi-asserted-by":"crossref","unstructured":"van der Lienden Mjc, Gaspar P, Boot R, Aerts J, van Eijk M. Glycoprotein non-metastatic protein B: An emerging biomarker for lysosomal dysfunction in macrophages. Int J Molsci. 2018;20(1).","DOI":"10.3390\/ijms20010066"},{"issue":"1","key":"4054_CR56","doi-asserted-by":"publisher","first-page":"e0147208","DOI":"10.1371\/journal.pone.0147208","volume":"11","author":"AR Marques","year":"2016","unstructured":"Marques AR, Gabriel TL, Aten J, van Roomen CP, Ottenhoff R, Claessen N, et al. Gpnmb is a potential Marker for the visceral pathology in Niemann-pick type C disease. PLoS One. 2016;11(1):e0147208.","journal-title":"PLoS One"},{"issue":"1","key":"4054_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ijc.2910600111","volume":"60","author":"MA Weterman","year":"1995","unstructured":"Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP. Nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995;60(1):73\u201381.","journal-title":"Int. J. Cancer"},{"issue":"5","key":"4054_CR58","first-page":"570","volume":"1","author":"XM Gong","year":"2019","unstructured":"Gong XM, Li YF, Luo J, Wang JQ, Wei J, Wang JQ, et al. Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance. Nat Metab. 2019;1(5):570\u201383.","journal-title":"NatMetab"},{"issue":"1","key":"4054_CR59","first-page":"81","volume":"30","author":"MG Anderson","year":"2002","unstructured":"Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA\/2J mice. Nat Genet. 2002;30(1):81\u201385.","journal-title":"NatGenet"},{"issue":"10","key":"4054_CR60","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.febslet.2008.03.030","volume":"582","author":"MH Sheng","year":"2008","unstructured":"Sheng MH, Wergedal JE, Mohan S, Lau KH. Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett. 2008;582(10):1451\u201358.","journal-title":"FEBSLett"},{"issue":"10","key":"4054_CR61","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.4049\/jimmunol.178.10.6557","volume":"178","author":"VM Ripoll","year":"2007","unstructured":"Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol. 2007;178(10):6557\u201366.","journal-title":"The JImmunol"},{"issue":"1\u20132","key":"4054_CR62","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.gene.2008.01.014","volume":"413","author":"VM Ripoll","year":"2008","unstructured":"Ripoll VM, Meadows NA, Raggatt LJ, Chang MK, Pettit AR, Cassady AI, Hume DA. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene. 2008;413(1\u20132):32\u201341.","journal-title":"Gene"},{"issue":"13","key":"4054_CR63","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.yexcr.2008.02.006","volume":"314","author":"SM Abdelmagid","year":"2008","unstructured":"Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, et al. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res. 2008;314(13):2334\u201351.","journal-title":"Exp CellRes"},{"key":"4054_CR64","doi-asserted-by":"publisher","first-page":"674739","DOI":"10.3389\/fimmu.2021.674739","volume":"12","author":"M Saade","year":"2021","unstructured":"Saade M, Araujo de Souza G, Scavone C, Kinoshita PF. The role of GPNMB in inflammation. Front Immunol. 2021;12:674739.","journal-title":"Front Immunol"},{"issue":"5","key":"4054_CR65","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","volume":"173","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 2018;173(5):1073\u201381.","journal-title":"Cell"},{"issue":"3","key":"4054_CR66","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566\u201381 e9.","journal-title":"Immunity"},{"issue":"1","key":"4054_CR67","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40478-018-0612-3","volume":"6","author":"M Huttenrauch","year":"2018","unstructured":"Huttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, et al. Glycoprotein NMB: A novel Alzheimer\u2019s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6(1):108.","journal-title":"Acta Neuropathol Commun"},{"key":"4054_CR68","first-page":"1","volume":"120","author":"EB Moloney","year":"2018","unstructured":"Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson\u2019s disease patients and increases after lysosomal stress. Neurobiol Dis. 2018;120:1\u201311.","journal-title":"NeurobiolDis"},{"issue":"9","key":"4054_CR69","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/2211-5463.12078","volume":"6","author":"G Kramer","year":"2016","unstructured":"Kramer G, Wegdam W, Donker-Koopman W, Ottenhoff R, Gaspar P, Verhoek M, et al. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 gaucher disease patients and mouse models. FEBS Open Bio. 2016;6(9):902\u201313.","journal-title":"FEBS Open Bio"},{"issue":"3","key":"4054_CR70","doi-asserted-by":"publisher","first-page":"e32419","DOI":"10.1371\/journal.pone.0032419","volume":"7","author":"MK Parente","year":"2012","unstructured":"Parente MK, Rozen R, Cearley CN, Wolfe JH. Dysregulation of gene expression in a lysosomal storage disease varies between brain regions implicating unexpected mechanisms of neuropathology. PLoS One. 2012;7(3):e32419.","journal-title":"PLoS One"},{"issue":"3","key":"4054_CR71","first-page":"78549","volume":"2006","author":"KS Hruska","year":"2006","unstructured":"Hruska KS, Goker-Alpan O, Sidransky E. Gaucher disease and the synucleinopathies. J Biomed Biotechnol. 2006;2006(3):78549.","journal-title":"J biomedbiotechnol"},{"key":"4054_CR72","doi-asserted-by":"publisher","first-page":"115042","DOI":"10.1016\/j.bone.2019.115042","volume":"128","author":"SH Peck","year":"2019","unstructured":"Peck SH, Tobias JW, Shore EM, Malhotra NR, Haskins ME, Casal ML, Smith LJ. Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII. Bone. 2019;128:115042.","journal-title":"Bone"},{"key":"4054_CR73","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3389\/fimmu.2017.01810","volume":"8","author":"DAE Hendrickx","year":"2017","unstructured":"Hendrickx DAE, van Scheppingen J, van der Poel M, Bossers K, Schuurman KG, van Eden CG, et al. Gene expression profiling of multiple sclerosis pathology identifies early patterns of demyelination surrounding chronic active lesions. Front Immunol. 2017;8:1810.","journal-title":"Front Immunol"},{"issue":"1","key":"4054_CR74","first-page":"7985","volume":"12","author":"LA Taghizadeh","year":"2022","unstructured":"Taghizadeh LA, King CJ, Nascene DR, Gupta AO, Orchard PJ, Higgins L, et al. Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy. Sci Rep. 2022;12(1):7985.","journal-title":"SciRep"},{"issue":"2","key":"4054_CR75","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/path.5875","volume":"257","author":"DC Salles","year":"2022","unstructured":"Salles DC, Asrani K, Woo J, Vidotto T, Liu HB, Vidal I, et al. GPNMB expression identifies TSC1\/2\/mTOR-associated and MiT family translocation-driven renal neoplasms. J Pathol. 2022;257(2):158\u201371.","journal-title":"JPathol"},{"key":"4054_CR76","doi-asserted-by":"crossref","unstructured":"Pastore N, Vainshtein A, Herz NJ, Huynh T, Brunetti L, Klisch TJ, et al. Nutrient-sensitive transcription factors TFEB and TFE3 couple autophagy and metabolism to the peripheral clock. The EMBOJ. 2019;38(12).","DOI":"10.15252\/embj.2018101347"},{"issue":"7608","key":"4054_CR77","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature18014","volume":"534","author":"HJ Shin","year":"2016","unstructured":"Shin HJ, Kim H, Oh S, Lee JG, Kee M, Ko HJ, et al. AMPK-SKP2-CARM1 signalling cascade in transcriptional regulation of autophagy. Nature. 2016;534(7608):553\u201357.","journal-title":"Nature"},{"key":"4054_CR78","doi-asserted-by":"crossref","unstructured":"Ma Q, Long S, Gan Z, Tettamanti G, Li K, Tian L. Transcriptional and Post-transcriptional regulation of autophagy. Cells. 2022;11(3).","DOI":"10.3390\/cells11030441"},{"issue":"228","key":"4054_CR79","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.2002790","volume":"5","author":"A Roczniak-Ferguson","year":"2012","unstructured":"Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42.","journal-title":"Sci Signal"},{"issue":"1","key":"4054_CR80","doi-asserted-by":"publisher","first-page":"e212779","DOI":"10.1148\/radiol.212779","volume":"307","author":"S D\u2019Amore","year":"2023","unstructured":"D\u2019Amore S, Sano H, Chappell DDG, Chiarugi D, Baker O, Page K, et al. Radiographic cortical thickness index predicts fragility fracture in Gaucher disease. Radiology. 2023;307(1):e212779.","journal-title":"Radiology"},{"issue":"2","key":"4054_CR81","first-page":"361","volume":"50","author":"G Adusumilli","year":"2021","unstructured":"Adusumilli G, Kaggie JD, D\u2019Amore S, Cox TM, Deegan P, MacKay JW, et al. Improving the quantitative classification of erlenmeyer flask deformities. Skeletal Radiol. 2021;50(2):361\u201369.","journal-title":"SkeletalRadiol"},{"issue":"11","key":"4054_CR82","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of gaucher disease. Am J Hematol. 2016;91(11):1082\u201389.","journal-title":"Am JHematol"},{"key":"4054_CR83","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","volume":"10","author":"NJ Weinreb","year":"2015","unstructured":"Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, Amato D. Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Raredis. 2015;10:64.","journal-title":"Orphanet J raredis"},{"issue":"6","key":"4054_CR84","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"4054_CR85","first-page":"1430","volume":"36","author":"I Markaki","year":"2021","unstructured":"Markaki I, Ntetsika T, Sorjonen K, Svenningsson P, BioPark Study G. Euglycemia indicates favorable motor outcome in Parkinson\u2019s disease. Mov Disord. 2021;36(6):1430\u201334.","journal-title":"MovDisord"},{"issue":"8","key":"4054_CR86","first-page":"971","volume":"24","author":"N Rifai","year":"2006","unstructured":"Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. NatBiotechnol. 2006;24(8):971\u201383.","journal-title":"NatBiotechnol"},{"issue":"9","key":"4054_CR87","first-page":"1635","volume":"52","author":"N Rifai","year":"2006","unstructured":"Rifai N, Gerszten RE. Biomarker discovery and validation. Clin Chem. 2006;52(9):1635\u201337.","journal-title":"ClinChem"},{"issue":"1","key":"4054_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18\/PARC in gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103(1):33\u201339.","journal-title":"Blood"},{"issue":"6","key":"4054_CR89","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/1873-3468.12104","volume":"590","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz MJ, Marques AR, Appelman MD, Verhoek M, Strijland A, Mirzaian M, et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases. FEBS Lett. 2016;590(6):716\u201325.","journal-title":"FEBSLett"},{"key":"4054_CR90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","volume":"11","author":"BE Smid","year":"2016","unstructured":"Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in gaucher disease type 1 patients. Orphanet J Raredis. 2016;11:28.","journal-title":"Orphanet J raredis"},{"issue":"3","key":"4054_CR91","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile gaucher disease. J Neurochem. 1982;39(3):709\u201318.","journal-title":"JNeurochem"},{"key":"4054_CR92","doi-asserted-by":"crossref","unstructured":"Vernet Machado Bressan Wilke M, Iop GD, Faqueti L, da Silva LA L, Kubaski F, Poswar FO, et al. A Brazilian rare-disease Center\u2019s experience with Glucosylsphingosine (lyso-Gb1) in patients with Gaucher disease: Exploring a novel correlation with IgG levels in plasma and a biomarker measurement in CSF. Int J Molsci. 2024;25(5).","DOI":"10.3390\/ijms25052870"},{"issue":"2","key":"4054_CR93","first-page":"234","volume":"54","author":"F Shi","year":"2014","unstructured":"Shi F, Duan S, Cui J, Yan X, Li H, Wang Y, et al. Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression. J Mol Neurosci. 2014;54(2):234\u201342.","journal-title":"J MolNeurosci"},{"issue":"2","key":"4054_CR94","doi-asserted-by":"publisher","first-page":"e0116644","DOI":"10.1371\/journal.pone.0116644","volume":"10","author":"F Szulzewsky","year":"2015","unstructured":"Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T, et al. Glioma-associated microglia\/macrophages display an expression profile different from M1 and M2 polarization and highly express gpnmb and Spp1. PLoS One. 2015;10(2):e0116644.","journal-title":"PLoS One"},{"issue":"12","key":"4054_CR95","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain. 2017;140(12):3191\u2013203.","journal-title":"Brain"},{"issue":"1","key":"4054_CR96","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10719-021-10023-x","volume":"39","author":"KL Wallom","year":"2022","unstructured":"Wallom KL, Fernandez-Suarez ME, Priestman DA, Te Vruchte D, Huebecker M, Hallett PJ, et al. Glycosphingolipid metabolism and its role in ageing and Parkinson\u2019s disease. Glycoconj J. 2022;39(1):39\u201353.","journal-title":"GlycoconjJ"},{"issue":"2","key":"4054_CR97","first-page":"418","volume":"23","author":"L Boccuto","year":"2014","unstructured":"Boccuto L, Aoki K, Flanagan-Steet H, Chen CF, Fan X, Bartel F, et al. A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum Molgenet. 2014;23(2):418\u201333.","journal-title":"Hum molgenet"},{"key":"4054_CR98","first-page":"85","volume":"112","author":"RN Alcalay","year":"2018","unstructured":"Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, et al. Alpha galactosidase a activity in Parkinson\u2019s disease. Neurobiol Dis. 2018;112:85\u201390.","journal-title":"NeurobiolDis"},{"issue":"5","key":"4054_CR99","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/path.4328","volume":"232","author":"BR Smith","year":"2014","unstructured":"Smith BR, Santos MB, Marshall MS, Cantuti-Castelvetri L, Lopez-Rosas A, Li G, et al. Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol. 2014;232(5):509\u201321.","journal-title":"JPathol"},{"issue":"6","key":"4054_CR100","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","volume":"78","author":"M Anheim","year":"2012","unstructured":"Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012;78(6):417\u201320.","journal-title":"Neurology"},{"issue":"7","key":"4054_CR101","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","volume":"89","author":"N Malek","year":"2018","unstructured":"Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, et al. Features of GBA-associated Parkinson\u2019s disease at presentation in the UK tracking Parkinson\u2019s study. J Neurol Neurosurg Psychiatry. 2018;89(7):702\u201309.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"4054_CR102","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","volume":"33","author":"G Bultron","year":"2010","unstructured":"Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson\u2019s disease in type 1 gaucher disease. J Inherit Metabdis. 2010;33(2):167\u201373.","journal-title":"J Inherit metabdis"},{"key":"4054_CR103","first-page":"763777","volume":"14","author":"K Tiklova","year":"2021","unstructured":"Tiklova K, Gillberg L, Volakakis N, Lunden-Miguel H, Dahl L, Serrano GE, et al. Disease duration influences gene expression in neuromelanin-positive cells from Parkinson\u2019s disease patients. Front Molneurosci. 2021;14:763777.","journal-title":"Front molneurosci"},{"issue":"1","key":"4054_CR104","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood.V89.1.315","volume":"89","author":"S Hashimoto","year":"1997","unstructured":"Hashimoto S, Yamada M, Motoyoshi K, Akagawa KS. Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. Blood. 1997;89(1):315\u201321.","journal-title":"Blood"},{"key":"4054_CR105","doi-asserted-by":"crossref","unstructured":"Zhang XJ, Cui ZH, Dong Y, Liang XW, Zhao YX, Baranova A, et al. GPNMB contributes to a vicious circle for chronic obstructive pulmonary disease. Biosci Rep. 2020;40(6).","DOI":"10.1042\/BSR20194459"},{"issue":"1","key":"4054_CR106","first-page":"136","volume":"6","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang X, Long M, Yuan M, Yin J, Luo W, et al. Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis. Commun Biol. 2023;6(1):136.","journal-title":"CommunBiol"},{"key":"4054_CR107","doi-asserted-by":"publisher","first-page":"814533","DOI":"10.3389\/fimmu.2022.814533","volume":"13","author":"PJ Palisoc","year":"2022","unstructured":"Palisoc PJ, Vaikutis L, Gurrea-Rubio M, Model EN, O\u2019Mara M, Ory S, et al. Functional characterization of glycoprotein nonmetastatic melanoma protein B in scleroderma fibrosis. Front Immunol. 2022;13:814533.","journal-title":"Front Immunol"},{"key":"4054_CR108","first-page":"16920","volume":"5","author":"A Katayama","year":"2015","unstructured":"Katayama A, Nakatsuka A, Eguchi J, Murakami K, Teshigawara S, Kanzaki M, et al. Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis. Sci Rep. 2015;5:16920.","journal-title":"SciRep"},{"issue":"12","key":"4054_CR109","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","volume":"105","author":"BE Rosenbloom","year":"2005","unstructured":"Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: A study from the gaucher registry. Blood. 2005;105(12):4569\u201372.","journal-title":"Blood"},{"issue":"7","key":"4054_CR110","doi-asserted-by":"publisher","first-page":"e0181487","DOI":"10.1371\/journal.pone.0181487","volume":"12","author":"N Steiner","year":"2017","unstructured":"Steiner N, Hajek R, Sevcikova S, Borjan B, Johrer K, Gobel G, et al. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLoS One. 2017;12(7):e0181487.","journal-title":"PLoS One"},{"issue":"6","key":"4054_CR111","first-page":"439","volume":"87","author":"de Fost M","year":"2008","unstructured":"de Fost M, Out TA, de Wilde Fa, Tjin EP, Pals ST, van Oers Mh, et al. Immunoglobulin and free light chain abnormalities in gaucher disease type I: Data from an adult cohort of 63 patients and review of the literature. Ann Hematol. 2008;87(6):439\u201349.","journal-title":"AnnHematol"},{"issue":"1\u20132","key":"4054_CR112","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/10428199509054770","volume":"20","author":"L Shvidel","year":"1995","unstructured":"Shvidel L, Hurwitz N, Shtalrid M, Zur S, Oliver O, Berrebi A. Complex IgA gammopathy in Gaucher\u2019s disease. Leuk Lymphoma. 1995;20(1\u20132):165\u201368.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4054_CR113","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","volume":"32","author":"A Brautbar","year":"2004","unstructured":"Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A. Effect of enzyme replacement therapy on gammopathies in gaucher disease. Blood Cells Moldis. 2004;32(1):214\u201317.","journal-title":"Blood Cells moldis"},{"issue":"2","key":"4054_CR114","first-page":"161","volume":"160","author":"S Aschermann","year":"2010","unstructured":"Aschermann S, Lux A, Baerenwaldt A, Biburger M, Nimmerjahn F. The other side of immunoglobulin G: Suppressor of inflammation. Clin Expimmunol. 2010;160(2):161\u201367.","journal-title":"Clin expimmunol"},{"issue":"2","key":"4054_CR115","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/path.3021","volume":"226","author":"TM Cox","year":"2012","unstructured":"Cox TM, Cachon-Gonzalez MB. The cellular pathology of lysosomal diseases. J Pathol. 2012;226(2):241\u201354.","journal-title":"JPathol"},{"issue":"5","key":"4054_CR116","first-page":"101232","volume":"297","author":"A Prabata","year":"2021","unstructured":"Prabata A, Ikeda K, Rahardini EP, Hirata KI, Emoto N. GPNMB plays a protective role against obesity-related metabolic disorders by reducing macrophage inflammatory capacity. J Biol Chem. 2021;297(5):101232.","journal-title":"J BiolChem"},{"issue":"6","key":"4054_CR117","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1086\/302925","volume":"66","author":"V Koprivica","year":"2000","unstructured":"Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 gaucher disease. Am J Humgenet. 2000;66(6):1777\u201386.","journal-title":"Am J humgenet"},{"issue":"1","key":"4054_CR118","first-page":"81","volume":"90","author":"E Sobreira","year":"2007","unstructured":"Sobreira E, Pires RF, Cizmarik M, Grabowski GA. Phenotypic and genotypic heterogeneity in gaucher disease type 1: A comparison between Brazil and the rest of the world. Mol Genet Metab. 2007;90(1):81\u201386.","journal-title":"Mol GenetMetab"},{"issue":"4","key":"4054_CR119","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/qjmed\/hch036","volume":"97","author":"RH Lachmann","year":"2004","unstructured":"Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher\u2019s disease. QJM. 2004;97(4):199\u2013204.","journal-title":"QJM"},{"key":"4054_CR120","doi-asserted-by":"crossref","unstructured":"Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, Sidransky E. Divergent phenotypes in gaucher disease implicate the role of modifiers. J Medgenet. 2005;42(6):e37.","DOI":"10.1136\/jmg.2004.028019"}],"updated-by":[{"DOI":"10.1186\/s13023-025-04143-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04054-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:03:02Z","timestamp":1763452982000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04054-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4054"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04054-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-025-04143-y","URL":"https:\/\/doi.org\/10.1186\/s13023-025-04143-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was given by the national ethics review committee (14\/EE\/1168) under the purview of the NHS Research and Development (R&D) in the United Kingdom and from the local R&D boards at each of the eight participating specialist clinical centers. Informed consent was obtained from all subjects at the time of enrolment into GAUCHERITE. The research cohort is registered with ClinicalTrials.gov, NCT code, 03240653. Ethical approval for the Parkinson\u2019s disease cohort (BioPark cohort) was obtained from the local ethics review board at the Karolinska Institute, Sweden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"No restrictions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We acknowledge some limitations to our study. Plasma gpNMB concentrations were analysed in patients who were already on treatment. Since analyses were performed at a specific time for all patients, long-term gpNMB alterations during the disease process were not captured in this study. Additionally, the relatively small number of patients receiving SRT may limit the statistical power to detect subtle differences between treatment modalities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Limitations of the study"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"545"}}